NCT06346600Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Skyline Therapeutics
Start Date
4/2/2024
Completion Date
3/1/2031
Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility Criteria
Age Range: 50 years to No maximum
Inclusion Criteria:
Subjects who only meet all of the following criteria are eligible for this study:
* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
Exclusion Criteria:
* Subjects who are judged by the investigator unsuitable for this study
Interventions
GENETIC
SKG0106
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Locations
Ophthalmic Consultants of Boston
Boston, Massachusetts 02114
United States
Retina Consultants of Texas
Katy, Texas 77494
United States
Wagner Macula & Retina Center
Norfolk, Virginia 23502
United States
The Second Hospital Of Anhui Medical University
Hefei, Anhui
China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang
China
Eye Hospital, WMU (Zhejiang Eye Hospital)
Wenzhou, Zhejiang
China
Beijing Hospital
Beijing,
China
Peking Union Medical College Hospital
Beijing,
China
EYE & ENT Hospital of Fudan University
Shanghai,
China
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine
Shanghai,
China